Bisoprolol Fumarate And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 42799-921
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Bisoprolol Fumarate And Hydrochlorothiazide (NDC 42799-921). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Edenbridge Pharmaceuticals Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
10mg 500 (10 mg 500 Count)
10mg 100ct
25 100 (25 mg 100 Count)
25mg 30 (25 mg 30 Count)
Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP are a medication used to treat high blood pressure. Each tablet contains 25mg of bisoprolol fumarate and 625mg of hydrochlorothiazide. The bottle contains 30 tablets. The text also includes some gibberish characters that may be a result of an error in the process.*
25 500 (25 mg 500 Count)
5mg 100 (5 mg 100 Count)
5mg 30 (5 mg 30 Count)
5mg 500 (5 mg 500 Count)
Biso Api Structure (Api Pic New1)
Hctz Api Structure (Api Pic New2)
Table 1 (Table 1 New)
The text is reporting results of a study on Sitting Systolic/Diastolic Blood Pressure (BP) and Heart Rate (HR) reduction after 3.4 weeks of treatment with different drugs. The table presents the study results for Placebo, BSH6.25, H625mg, B3/H62smg, and BI0/H625 drugs in Study 1 and Study 2. The study reports the mean decrease (A) for BP and HR and the observed mean change from baseline minus placebo.*
Table-3 (Table 3 New)
Table-2 (Table New 2)
This appears to be a table containing data on serum potassium levels in a study conducted in the US. The study was likely placebo-controlled, but there is not enough information to determine the specifics. The table shows mean change in serum potassium levels measured in mEq/L between 2004 and 7011 for both the Placebo and the treatment group ("B10)"). It also indicates the percentage of participants who experienced hypokalemia (low potassium levels) in each group.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.